Detail of the clinical trial

Title of the trial A Phase 3, Randomized Study of Zanubrutinib (BGB-311) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
EudraCT number 2018-001366-42
Protocol number BGB-3111-305
Sponsor BeiGene, Ltd., c/o Mourant Ozannes Corporate Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, PO Box 1348, Grand Cayman Ky1-1108, Cayman Islands
Indications Hemato-oncology
Diagnosis Chronic Lymphocytic Leukemia
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2018
Date of approval by Institute (SÚKL) 28.2.2019
Date of approval by EC 25.10.2018
Date of initiation CT in ČR 29.4.2019
Date of ending CT in ČR
Sites Fakultní nemocnice Brno, Interní hematologická a onkologická klinika, Jihlavská 20, Brno, 625 00
Fakultní nemocnice Hradec Králové, IV. Interní hematologická klinika, Sokolská 581, Hradec Králové 500 05
Fakultní nemocnice Olomouc, Hemato-onkologická klinika, I.P. Pavlova 6 ,Olomouc,779 00
Fakultní nemocnice Ostrava, Klinika hematoonkologie, 17. listopadu 1790, Ostrava - Poruba, 708 52

‹‹ Back to list